Amgen’s Post

Exciting News from C-Path's Translational Therapeutics Accelerator! We're thrilled to announce a new $250,000 research grant awarded to Daniela Zarnescu, Ph.D., Professor of Cellular and Molecular Physiology at Penn State University College of Medicine, in collaboration with Jon Njardarson, Ph.D., Professor at the University of Arizona. Their groundbreaking project, titled “Novel Small Molecules with Neuroprotective Potential in ALS and Related Neurodegenerative Diseases,” aims to make significant strides in the fight against neurodegenerative diseases like amyotrophic lateral sclerosis. Dr. Zarnescu, expressing her excitement about the grant, said, “I am honored to receive this grant from TRxA, alongside my collaborator Dr. Jon Njardarson. Together, we will explore new avenues in neuroprotective therapies for ALS and related diseases. This funding will accelerate our efforts to discover novel treatments that can impact the lives of patients living with these challenging conditions.” Maaike Everts, Ph.D., TRxA Executive Director, added, “We are thrilled to support Dr. Zarnescu and Dr. Njardason’s pioneering research through TRxA. Their collaborative approach aligns perfectly with C-Path’s mission to accelerate the development of therapies for devastating diseases like ALS. This grant underscores our commitment to advancing scientific discovery that can translate into tangible benefits for patients.” Read the full details, here: https://lnkd.in/gzpzi5Vu #CPath #TRxA #ALS #amyotrophiclateralsclerosis #Neurodegeneration #ALSResearch #CPath #ScientificDiscovery #drugdevelopment #globalhealth #raredisease

Intestinal organoids are transforming the way we study the gut and its complex cellular landscape. This recent article highlights exciting advancements and future directions in organoid research. Key Insights: 🔬 Organoids replicate the intricate cellular diversity of the small intestine, from abundant enterocytes to rare cell types like tuft cells and M-cells. 🔬 Innovative enrichment techniques enable deeper studies of rare cell populations, advancing our understanding of differentiation and disease mechanisms. 🔬 Applications are far-reaching, from studying stem cell biology to informing personalized therapies for conditions such as diabetes and immune-related disorders. These breakthroughs demonstrate how organoids are opening new avenues for investigating human biology and accelerating progress in medicine, proving to be invaluable tools for researchers worldwide. At MIMETAS, we’re proud to leverage these advancements in our 3D human gut models to support cutting-edge research and innovation. 🔗 Read the article here: https://lnkd.in/gj8JmJUs #Organoids #IntestinalResearch #Biotechnology #InnovationInScience

At NEURO-SYS, we are a leading preclinical CRO specialized in neurodegenerative diseases such as ALS. Our mission is to support clients in driving groundbreaking research and therapeutic discoveries for these devastating conditions. This ALS Awareness Month, we reaffirm our commitment as a strategic partner empowering biotech and pharmaceutical companies through our scientific expertise and state-of-the-art preclinical capabilities. We pioneer innovative approaches to elucidate disease biology and accelerate the evaluation of promising therapeutic candidates. From study design to execution, our specialized neurodegenerative disease focus enables us to guide clients at every step, applying scientific rigor to keep their programs on the cutting edge. Join us as we fuel pioneering research and discovery efforts to unlock a future free from the burden of ALS and related neurodegenerative diseases. https://lnkd.in/dPKfqquy #LouGehrigsDisease #HopeForACure #FightAgainstALS #ALSAwareness #EndALS #Neuroscience #ALSResearch #DrugDiscovery

Abstract on ACD856’s anti-inflammatory effects to be presented at a leading Alzheimer’s conference Today we announced that an abstract with preclinical data on NeuroRestore ACD856 demonstrating its anti-inflammatory and immunomodulatory effects has been accepted for presentation at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, which this year is being held in Madrid, Spain, on October 29 – November 1. The abstract, titled Preclinical evidence for anti-inflammatory and immunomodulatory effects of NeuroRestore ACD856, a Trk-PAM in clinical development for the treatment of Alzheimer’s disease, will be presented at the conference by Dr. Cristina Parrado-Fernández, Senior Scientist at AlzeCure. The other authors are Veronica Lidell, Azita Rasti, Maria Backlund, Gunnar Nordvall, Martin Jönsson, Johan Sandin and Pontus Forsell from AlzeCure Pharma, and Ruchi Gera, Sumonto Mitra and Prof. Maria Eriksdotter from Karolinska Institutet. The presentation includes new preclinical results with ACD856, the lead clinical drug candidate within the NeuroRestore platform. The data show that the substance shows both anti-inflammatory and immunomodulating properties, something that has been demonstrated after treatment in both aged animals and in Alzheimer's models. This indicates potentially disease-modifying properties of this class of molecules. To the press release: https://lnkd.in/dVsTCtRU The abstract and the poster will be available on AlzeCure’s website after the presentation https://lnkd.in/dnVm8J3f #alzecure #neurorestore #alzheimer #dementia #neuroscience #ACD856 #alzheimerfonden #nordnet #avanza #redeye #aktiespararna #swedbank #analysguiden #finwire #placera

We are happy to announce that Professor Daniel Kaganovich has joined Rafa's Moonshot as a Strategic Advisor for Small Molecule Drug Discovery and Translational Assay Development 🌟 Prof. Kaganovich brings a unique blend of expertise: 15 years as a professor studying the mechanisms of rare neurological diseases, building biotech startups, and serving as VP of Neurobiology in a Pharma company focused on neurodegenerative therapeutics. Here are a few key highlights about him: 📜 Prof. Kaganovich received his AB degree from Harvard University and did a PhD at Stanford University. His PhD work led to the creation of a new platform for investigating protein association in live cells. 🧪 In his early work, which was published in Nature journal, Prof. Kaganovich discovered a new cell biological phenomenon which is now recognized as the central driver of neurodegenerative pathology in diseases like ALS, Parkinson's, and Dementia. 🤝 In 2019, Prof. Kaganovich co-founded 1Base Pharmaceuticals, a company developing curative drugs for ALS patients. 💡 With many years of experience in drug discovery, Prof. Kaganovich is committed to advancing novel drug discovery ideas from basic research to drug development pipelines. At Rafa's Moonshot, he will steer small molecule drug discovery for STXBP1 and assist in translational assay development. Join us in welcoming Prof. Daniel Kaganovich to our team! His dedication and expertise are invaluable as we continue our mission to find a cure for STXBP1 and bring hope to families affected by rare genetic diseases. 🔬 Follow our journey on LinkedIn to stay updated on our latest research developments and team achievements! #Welcome #Neuroscience #STXBP1 #RafasMoonshot #RareDiseases #Innovation #Research

The recent launch of Booster Therapeutics and their development of a new class of proteosome activator medicines, the exciting news from the Centre for Targeted Protein Degradation who’ve announced their success in generating 3D snapshots of degraders in action and the first clinical trial by Arvinas ongoing, the momentum for investigating protein degraders as a treatment of neurodegenerative diseases is gaining rapidly. Therefore, I’m super excited to announce that the 2nd Protein Degradation for CNS Summit is back to unite experts in neuroscience, medicinal chemistry, protein sciences and structural biology for an industry-leading look into the latest developments in the field. Full agenda here: : https://ter.li/e4cqv3 Here’s a session spotlight: 🔬 PROTAC LRRK2 Degrader Molecules as Potential Disease Modifying Therapeutics for Neurodegenerative Diseases, 𝗔𝗿𝘃𝗶𝗻𝗮𝘀 🔬Harnessing the AUTOTAC Platform for Development of a First-In-Class Tau Aggregate Degrader: Bridging the Gap Between Discovery, Preclinical Candidacy & Clinical Trials, 𝗔𝗨𝗧𝗢𝗧𝗔𝗖 𝗕𝗶𝗼 🔬Activation of Parkin by a Molecular Glue, 𝗕𝗶𝗼𝗴𝗲𝗻 Speakers include: Beth J Hoffman Chang Hoon Ji Christopher Hickey, PhD Emiliano Biasini Jennifer Johnston, Ph.D. Jessica Foley, PhD Laura Silvian Lili Zhang Magnus Walter Marianthi Papakosta, Ph.D. Michal J. Walczak Mikolaj Slabicki Paul Park Patrick Wen Pranam Chatterjee Rajaraman Krishnan Shourya Sonkar Roy Burman Simon Glerup William Farnaby Jiho Park #Proteindegradation #proteindegrader #neurodegenerativedisease #CNSdiseases #neuroscience #PROTAC #AUTOTAC #Molecularglue

embryonic basis of cancer. and how to help digesting negatively charged protein coating of cancer cells to expose them to white blood cells and eventually to stop their multiplexing. forgotten story since 1911. nature has it all. just needs honest eyes to see. very interesting read.

Biogen and Neomorph, Inc. have entered a research partnership aimed at discovering and developing molecular glue degraders for the treatment of Alzheimer’s disease and other neurological and immunological conditions. Neomorph CEO, co-founder and president Phil Chamberlain stated: “Neomorph’s molecular glue degrader platform represents a unique approach to drug discovery. We are excited to partner with Biogen, a leader in Alzheimer’s, rare and immunological diseases, to explore the potential of our technology in addressing some of the most challenging and valuable targets in these fields.” Biogen research head Jane Grogan stated: “As part of our modality agnostic research strategy, Biogen is committed to investing in new approaches to unlock biological targets that have remained difficult to reach. This collaboration with Neomorph reflects the approach we want to take to pair our internal drug development expertise with cutting-edge external innovation to create clinically meaningful therapies for patients.” Click here for the full article - https://lnkd.in/dbEWzp7a #pharma #molecularglue #neurology #immunology #alzheimers #biopharma #biotech

"Evolution of Antimicrobial Peptides" It's been 13 years since I first heard about the Antimicrobial Peptides and started working on as my PhD research work. I am still fascinated with AMPs and all my thoughts and research projects revolve around them, even when I come across different research areas such as molecular biology, infection biology, Immunology, radiation oncology, and genome editing, during my research journey. I am thrilled to share the online presence of my first scientific book at Springer Nature containing 13 chapters with 35 contributing authors. https://lnkd.in/grqQBu87 Hard copies will be available soon to order on Amazon. https://lnkd.in/gZifuvXV Santi M Mandal DM me if you are interested in having a personal copy of this book. A special thanks and congratulations to all the contributing authors who make this project successful. Dr. Mitali Mishra, PhD, Dr. Sumeeta kumari, Dr. Alka dHIMAN, DR. SK AFTABUL ALAM, Dr. Dinata Roy, Arati Chettri, Dr. Dr Varisha Anjum, Dr. Kanti Nandan, Dr. Priyanka Parhi, Dr. Gurpreet kaur, Dr. Pradeep Nag #antimicrobialpeptides #evolution #therapeutics #selfdefense

🎉 I'm glad to share our latest publication in Scientific Reports, in collaboration with Céline Auxenfans, Ali Mojallal. MD, PhD, Clément Bellanger, Hakima A. and Philippe Delannoy. "Deciphering influence of donor age on adipose-derived stem cells: in vitro paracrine function and angiogenic potential" is digging into donor age on characteristics and angiogenesis promotion of Adipose derived Stem/Stromal Cells. ⬇ Link for article ⬇ https://lnkd.in/ewv4xpDa